Pharmacokinetic Profiles of Gabapentin after Oral and Subcutaneous Administration in Black-tailed Prairie Dogs ().
Patrick O Mills, Cassandra O Tansey, Sarah C Genzer, Matthew R Mauldin, Rex A Howard, Chantal A Kling, Felix R Jackson, Audrey M Matheny, Dawn M Boothe, George W Lathrop, Nathaniel Powell, Nadia Gallardo-Romero
Author Information
Patrick O Mills: Comparative Medicine Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
Cassandra O Tansey: Comparative Medicine Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
Sarah C Genzer: Comparative Medicine Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
Matthew R Mauldin: Poxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
Rex A Howard: Comparative Medicine Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
Chantal A Kling: Poxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia; Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee.
Felix R Jackson: Poxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
Audrey M Matheny: Poxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia; Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee.
Dawn M Boothe: Clinical Pharmacology Laboratory, Auburn University, Auburn, Alabama.
George W Lathrop: Comparative Medicine Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
Nathaniel Powell: Comparative Medicine Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
Nadia Gallardo-Romero: Poxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia;, Email: hfa5@cdc.gov.
In veterinary and human medicine, gabapentin (a chemical analog of γ-aminobutyric acid) is commonly prescribed to treat postoperative and chronic neuropathic pain. This study explored the pharmacokinetics of oral and subcutaneous administration of gabapentin at high (80 mg/kg) and low (30 mg/kg) doses as a potential analgesic in black-tailed prairie dogs (; = 24). The doses (30 and 80 mg/kg) and half maximal effective concentration (1.4 to 16.7 ng/mL) for this study were extrapolated from pharmacokinetic efficacy studies in rats, rabbits, and cats. Gabapentin in plasma was measured by using an immunoassay, and data were evaluated using noncompartmental analysis. The peak plasma concentrations (mean ±1 SD) were 42.6 ±14.8 and 115.5 ±15.2 ng/mL, respectively, after 30 and 80 mg/kg SC and 14.5 ±3.5 and 20.7 ±6.1 ng/mL after the low and high oral dosages, respectively. All peak plasma concentrations of gabapentin occurred within 5 h of administration. Disappearance half-lives for the low and high oral doses were 7.4 ± 6.0 h and 5.0 ± 0.8 h, respectively. The results of this study demonstrate that oral administration of gabapentin at low (30 mg/kg) doses likely would achieve and maintain plasma concentrations at half maximum effective concentration for 12 h, making it a viable option for an every 12-h treatment.
